José Sánchez-Payá

Dr. José Sánchez-Payá

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
OMOscar Moreno-Perez
Oscar Moreno-Perez
Mariano AndrésMariano Andrés
Mariano Andrés
Jose-Manuel Ramos-RinconJose-Manuel Ramos-Rincon
Jose-Manuel Ramos-Rincon
JSJosé Sánchez-Payá
José Sánchez-Payá
JRJuan Carlos Rodríguez
Juan Carlos Rodríguez
EMEsperanza Merino
Esperanza Merino

19 December 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
GTGinger Giorgiana Cabrera Tejada
Ginger Giorgiana Cabrera Tejada
PCPablo Chico-Sánchez
Pablo Chico-Sánchez
PGPaula Gras-Valenti
Paula Gras-Valenti
FJFrancisco A. Jaime-Sánchez
Francisco A. Jaime-Sánchez
MGMaria Galiana-Ivars
Maria Galiana-Ivars
ERElena Ronda-Perez
Elena Ronda-Perez
Healthcare-associated infections (HAIs) present a global public health challenge, contributing to high morbidity and mortality and substantial economic burdens. Ventilator-associated pneumonia (VAP) ranks as the second most prevalent HAI in intensive care units (ICUs), emphasizing the need for economic analyses in this context. This retrospective cohort study, conducted at the General Hospital of Alicante from 2012 to 2019, aimed to assess additional costs related to VAP by comparing the extended length of stay for infected and non-infected ICU patients undergoing mechanical ventilation (MV) for more than 48 h. Employing propensity score association, 434 VAP patients were compared to an equal number without VAP. The findings indicate a significantly longer mechanical ventilation period for VAP patients (17.40 vs. 8.93 days, p < 0.001), resulting in an extra 13.56 days of stay and an additional cost of EUR 20,965.28 per VAP episode. The study estimated a total cost of EUR 12,348,965.28 for VAP during the study period, underscoring the economic impact of VAP. These findings underscore the urgent need for rigorous infection surveillance, prevention, and control measures to enhance healthcare quality and reduce overall expenditures.

1 March 2014 in Human Pathology
Verified
Journal Article
Closed access
FOFernando Ortiz-Martínez
Fernando Ortiz-Martínez
APAriadna Perez-Balaguer
Ariadna Perez-Balaguer
DCDaniel Ciprián
Daniel Ciprián
LALeire Andrés
Leire Andrés
JPJosé Ponce
José Ponce
GPGloria Peiró
Gloria Peiró

1 May 2009 in Journal of Hospital Infection
Verified
Journal Article
Closed access
JSJosé Sánchez-Payá
José Sánchez-Payá
CBC. Bischofberger
C. Bischofberger
MLM. Lizan
M. Lizan
JLJ. Lozano
J. Lozano
EPE. Muñoz Platón
E. Muñoz Platón
JVJ.A. Vicente
J.A. Vicente

1 December 2020 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
NANatividad Algado-Sellés
Natividad Algado-Sellés
PGPaula Gras-Valentí
Paula Gras-Valentí
PCPablo Chico-Sánchez
Pablo Chico-Sánchez
JMJuan G. Mora-Muriel
Juan G. Mora-Muriel
VSVictor M. Soler-Molina
Victor M. Soler-Molina
JSJosé Sánchez-Payá
José Sánchez-Payá

7 December 2011 in Vaccine
Verified
Journal Article
Closed access
JSJosé Sánchez-Payá
José Sánchez-Payá
IHIgnacio Hernández-García
Ignacio Hernández-García
VGVicente García-Román
Vicente García-Román
RCRobert Camargo-Angeles
Robert Camargo-Angeles
JBJulio Barrenengoa-Sañudo
Julio Barrenengoa-Sañudo
MGMaría González-Hernández
María González-Hernández